Skip to main content
| News

Bottneuro advancing personalized Alzheimer’s therapy

02.11.2021

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient’s brain are stimulated. In order to determine the correct areas of the brain for treatment, the spin-off from the University of Basel has turned to the imaging processes developed by Positrigo.

Three co-founders of Bottneuro: Bekim Osmani, Tino Töpper and Alois C. Hopf (img: Bottneuro)

One approach to treating Alzheimer’s disease is to eliminate substances that cause the disease by stimulating specific areas of the brain. This is the strategy being pursued by the startup Bottneuro, a spin-off from the University of Basel based at Technologiepark Basel. The company intends to establish a network of diagnostic centers for Alzheimer’s patients to offer personalized therapy approaches to those affected by the disease. The business magazine Forbes listed Bottneuro among the 30 best spin-offs situated in the German-speaking DACH (Germany, Austria and Switzerland) region to keep an eye on over the course of 2021.

For the development of its personalized therapy, Bottneuro is joining forces with Positrigo. The spin-off from the Swiss Federal Institute of Technology Zurich (ETH) specializes in the development of nuclear medicine imaging technologies. Bottneuro is planning to use a positron emission tomography (PET) device developed by Positrigo to accurately localize the correct areas of the brain to treat in Alzheimer’s patients.

The two startups have signed a Memorandum of Understanding (MoU) for the delivery of several NeuroLF-type brain PET imaging devices, Positrigo writes in a press release. These are to be delivered as soon as a CE mark is awarded to the NeuroLF. “We are delighted to agree this cooperation with Positrigo”, comments Bekim Osmani, Managing Director of Bottneuro, in the press release. “The NeuroLF brain PET device will enable us to offer cost-effective PET scans in our Alzheimer’s diagnostic centers in order to obtain important 3D data sets that we need for our personalized Alzheimer’s therapy”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.